Variability in hepatic expression of organic anion transporter 7/SLC22A9, a novel pravastatin uptake transporter: Impact of genetic and regulatory factors

Pharmacogenomics Journal

Volumn 16, Issue 4, 2016, Pages 341-351

  Emami Riedmaier, A ^a,b   Burk, O ^a,b   Van Eijck, B A C ^a,b   Schaeffeler, E ^a,b   Klein, K ^a,b   Fehr, S ^c   Biskup, S ^c   Muller S ^a,b   Winter, S ^a,b   Zanger, U M ^a,b   Schwab, M ^a,b,d   Nies, A T ^a,b  

^a DR MARGARETE FISCHER BOSCH INSTITUTE OF CLINICAL PHARMACOLOGY   (Germany)

^b UNIVERSITY OF TÜBINGEN   (Germany)

^c CEGAT GMBH   (Germany)

^d UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ESTRONE SULFATE; HEPATOCYTE NUCLEAR FACTOR 4ALPHA; MESSENGER RNA; ORGANIC ANION TRANSPORTER; ORGANIC ANION TRANSPORTER 7; PRAVASTATIN; UNCLASSIFIED DRUG; HEPATOCYTE NUCLEAR FACTOR 4; HNF4A PROTEIN, HUMAN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; SLC22A9 PROTEIN, HUMAN;

ARTICLE; CAUCASIAN; COMPUTER MODEL; CONTROLLED STUDY; DRUG UPTAKE; EMBRYO; GENE EXPRESSION; GENE SEQUENCE; GENETIC VARIABILITY; GENOTYPE; HETEROZYGOTE; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; LIVER; MISSENSE MUTATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; SLC22A9 GENE; GENE EXPRESSION REGULATION; GENETIC TRANSFECTION; GENETICS; HEK293 CELL LINE; KINETICS; METABOLISM; PHARMACOGENETIC VARIANT; PHENOTYPE; TRANSPORT AT THE CELLULAR LEVEL;

BIOLOGICAL TRANSPORT; EUROPEAN CONTINENTAL ANCESTRY GROUP; GENE EXPRESSION REGULATION; HEK293 CELLS; HEPATOCYTE NUCLEAR FACTOR 4; HETEROZYGOTE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; KINETICS; LIVER; MUTATION, MISSENSE; ORGANIC ANION TRANSPORTERS, SODIUM-INDEPENDENT; PHARMACOGENOMIC VARIANTS; PHENOTYPE; PRAVASTATIN; TRANSFECTION;

EID: 84938674597     PISSN: 1470269X     EISSN: 14731150     Source Type: Journal    
DOI: 10.1038/tpj.2015.55     Document Type: Article

References (46)

1. Koepsell H. The SLC22 family with transporters of organic cations, anions and zwitterions. Mol Aspects Med 2013; 34: 413-435
2. Burckhardt G. Drug transport by organic anion transporters (OATs). Pharmacol Ther 2012; 136: 106-130
3. Nies AT, Koepsell H, Damme K, Schwab M. Organic cation transporters (OCTs, MATEs), in vitro and in vivo evidence for the importance in drug therapy. Handb Exp Pharmacol 2011; 201: 105-167
4. Emami Riedmaier A, Nies AT, Schaeffeler E, Schwab M. Organic anion transporters and their implications in pharmacotherapy. Pharmacol Rev 2012; 64: 421-449
5. Stocker SL, Emami Riedmaier A, Schwab M, Giacomini KM. OCT (SLC22A) and OCTN family. In: Ishikawa T, Kim RB, König J (eds). Pharmacogenomics of Human Drug Transporters. Wiley, 2013, pp 171-208
6. Shin HJ, Anzai N, Enomoto A, He X, Kim DK, Endou H, et al. Novel liver-specific organic anion transporter OAT7 that operates the exchange of sulfate conjugates for short chain fatty acid butyrate. Hepatology 2007; 45: 1046-1055
7. Jacobsson JA, Haitina T, Lindblom J, Fredriksson R. Identification of six putative human transporters with structural similarity to the drug transporter SLC22 family. Genomics 2007; 90: 595-609
8. Nies AT, Koepsell H, Winter S, Burk O, Klein K, Kerb R, et al. Expression of organic cation transporters OCT1 (SLC22A1) and OCT3 (SLC22A3) is affected by genetic factors and cholestasis in human liver. Hepatology 2009; 50: 1227-1240
9. Nies AT, Niemi M, Burk O, Winter S, Zanger UM, Stieger B, et al. Genetics is a major determinant of expression of the human hepatic uptake transporter OATP1B1, but not of OATP1B3 and OATP2B1. Genome Med 2013; 5: 1
10. Nies AT, Hofmann U, Resch C, Schaeffeler E, Rius M, Schwab M. Proton pump inhibitors inhibit metformin uptake by organic cation uptake transporters (OCTs). PLoS ONE 2011; 6: e22163
11. Ekaratanawong S, Anzai N, Jutabha P, Miyazaki H, Noshiro R, Takeda M, et al. Human organic anion transporter 4 is a renal apical organic anion/dicarboxylate exchanger in the proximal tubules. J Pharmacol Sci 2004; 94: 297-304
12. Wolbold R, Klein K, Burk O, Nussler AK, Neuhaus P, Eichelbaum M, et al. Sex is a major determinant of CYP3A4 expression in human liver. Hepatology 2003; 38: 978-988
13. Hesselson SE, Matsson P, Shima JE, Fukushima H, Yee SW, Kobayashi Y, et al. Genetic variation in the proximal promoter of ABC and SLC superfamilies: liver and kidney specific expression and promoter activity predict variation. PLoS ONE 2009; 4: e6942
14. R Core Team. R: A Language and Environment for Statistical Computing. http://www.r-project.org 2014
15. Brouwer KL, Keppler D, Hoffmaster KA, Bow DA, Cheng Y, Lai Y, et al. In vitro methods to support transporter evaluation in drug discovery and development. Clin Pharmacol Ther 2013; 94: 95-112
16. Nies AT, Schwab M, Keppler D. Interplay of conjugating enzymes with OATP uptake transporters and ABCC/MRP efflux pumps in the elimination of drugs. Expert Opin Drug Metab Toxicol 2008; 4: 545-568
17. Letschert K, Faulstich H, Keller D, Keppler D. Molecular characterization and inhibition of amanitin uptake into human hepatocytes. Toxicol Sci 2006; 91: 140-149
18. Park JW, Siekmeier R, Merz M, Krell B, Harder S, Marz W, et al. Pharmacokinetics of pravastatin in heart-Transplant patients taking cyclosporin A. Int J Clin Pharmacol Ther 2002; 40: 439-450
19. Hedman M, Neuvonen PJ, Neuvonen M, Holmberg C, Antikainen M. Pharmacokinetics and pharmacodynamics of pravastatin in pediatric and adolescent cardiac transplant recipients on a regimen of triple immunosuppression. Clin Pharmacol Ther 2004; 75: 101-109
20. Kel AE, Gossling E, Reuter I, Cheremushkin E, Kel-Margoulis OV, Wingender E. MATCH: A tool for searching transcription factor binding sites in DNA sequences. Nucleic Acids Res 2003; 31: 3576-3579
21. Fang B, Mane-Padros D, Bolotin E, Jiang T, Sladek FM. Identification of a binding motif specific to HNF4 by comparative analysis of multiple nuclear receptors. Nucleic Acids Res 2012; 40: 5343-5356
22. Kiselyuk A, Lee SH, Farber-Katz S, Zhang M, Athavankar S, Cohen T, et al. HNF4alpha antagonists discovered by a high-Throughput screen for modulators of the human insulin promoter. Chem Biol 2012; 19: 806-818
23. Saborowski M, Kullak-Ublick GA, Eloranta JJ. The human organic cation transporter-1 gene is transactivated by hepatocyte nuclear factor-4alpha. J Pharmacol Exp Ther 2006; 317: 778-785
24. Knauer MJ, Girdwood AJ, Kim RB, Tirona RG. Transport function and transcriptional regulation of a liver-enriched Human Organic Anion Transporting Polypeptide 2B1 transcriptional start site variant. Mol Pharmacol 2013; 83: 1218-1228
25. Tegude H, Schnabel A, Zanger UM, Klein K, Eichelbaum M, Burk O. Molecular mechanism of basal CYP3A4 regulation by hepatocyte nuclear factor 4alpha: evidence for direct regulation in the intestine. Drug Metab Dispos 2007; 35: 946-954
26. Klein K, Jüngst C, Mwinyi J, Stieger B, Krempler F, Patsch W, et al. The human organic anion transporter genes OAT5 and OAT7 are transactivated by hepatocyte nuclear factor-1alpha (HNF-1alpha). Mol Pharmacol 2010; 78: 1079-1087
27. Klein K, Winter S, Turpeinen M, Schwab M, Zanger UM. Pathway-Targeted pharmacogenomics of CYP1A2 in human liver. Front Pharmacol 2010; 1: 129
28. Sauer B. Site-specific recombination: developments and applications. Curr Opin Biotechnol 1994; 5: 521-527
29. Shitara Y, Maeda K, Ikejiri K, Yoshida K, Horie T, Sugiyama Y. Clinical significance of organic anion transporting polypeptides (OATPs) in drug disposition: their roles in the hepatic clearance and intestinal absorption. Biopharm Drug Dispos 2013; 34: 45-78
30. Kunze A, Huwyler J, Camenisch G, Poller B. Prediction of OATP1B1 and OATP1B3 mediated hepatic uptake of statins based on transporter protein expression and activity data. Drug Metab Dispos 2014; 42: 1514-1521
31. SEARCH Collaborative Group. SLCO1B1 variants and statin-induced myopathy-A genomewide study. N Engl J Med 2008; 359: 789-799
32. Niemi M, Pasanen MK, Neuvonen PJ. Organic anion transporting polypeptide 1B1: a genetically polymorphic transporter of major importance for hepatic drug uptake. Pharmacol Rev 2011; 63: 157-181
33. König J, Müller F, Fromm MF. Transporters and drug-drug interactions: important determinants of drug disposition and effects. Pharmacol Rev 2013; 65: 944-966
34. Nakagomi-Hagihara R, Nakai D, Tokui T, Abe T, Ikeda T. Gemfibrozil and its glucuronide inhibit the hepatic uptake of pravastatin mediated by OATP1B1. Xenobiotica 2007; 37: 474-486
35. Nakagomi-Hagihara R, Nakai D, Tokui T. Inhibition of human organic anion transporter 3 mediated pravastatin transport by gemfibrozil and the metabolites in humans. Xenobiotica 2007; 37: 416-426
36. Watanabe T, Kusuhara H, Watanabe T, Debori Y, Maeda K, Kondo T, et al. Prediction of the overall renal tubular secretion and hepatic clearance of anionic drugs and a renal drug-drug interaction involving organic anion transporter 3 in humans by in vitro uptake experiments. Drug Metab Dispos 2011; 39: 1031-1038
37. Kyrklund C, Backman JT, Neuvonen M, Neuvonen PJ. Gemfibrozil increases plasma pravastatin concentrations and reduces pravastatin renal clearance. Clin Pharmacol Ther 2003; 73: 538-544
38. Penson MG, Fricker FJ, Thompson JR, Harker K, Williams BJ, Kahler DA, et al. Safety and efficacy of pravastatin therapy for the prevention of hyperlipidemia in pediatric and adolescent cardiac transplant recipients. J Heart Lung Transplant 2001; 20: 611-618
39. Goldstein JL, Brown MS. Regulation of the mevalonate pathway. Nature 1990; 343: 425-430
40. Lennernas H, Fager G. Pharmacodynamics and pharmacokinetics of the HMG-CoA reductase inhibitors. Similarities and differences. Clin Pharmacokinet 1997; 32: 403-425
41. Mosshammer D, Schaeffeler E, Schwab M, Mörike K. Mechanisms and assessment of statin-related muscular adverse effects. Br J Clin Pharmacol 2014; 78: 454-466
42. Wilke RA, Ramsey LB, Johnson SG, Maxwell WD, McLeod HL, Voora D, et al. The clinical pharmacogenomics implementation consortium: CPIC guideline for SLCO1B1 and simvastatin-induced myopathy. Clin Pharmacol Ther 2012; 92: 112-117
43. Hwang-Verslues WW, Sladek FM. HNF4alpha-role in drug metabolism and potential drug target?. Curr Opin Pharmacol 2010; 10: 698-705
44. Kamiyama Y, Matsubara T, Yoshinari K, Nagata K, Kamimura H, Yamazoe Y. Role of human hepatocyte nuclear factor 4alpha in the expression of drug-metabolizing enzymes and transporters in human hepatocytes assessed by use of small interfering RNA. Drug Metab Pharmacokinet 2007; 22: 287-298
45. NHLBI GO Exome Sequencing Project (ESP). Exome Variant Server 2014 p. http://evs.gs.washington.edu/EVS
46. Lorenz R, Bernhart SH, Honer Zu SC, Tafer H, Flamm C, Stadler PF, et al. ViennaRNA Package 2.0. Algorithms Mol Biol 2011; 6: 26